Nuveen LLC Takes Position in Celldex Therapeutics, Inc. $CLDX

Key Points

• Nuveen LLC has acquired 429,126 shares of Celldex Therapeutics, valued at approximately $7.79 million, representing about 0.65% ownership of the company.
• Celldex Therapeutics recently reported an EPS of (0.85), slightly exceeding expectations, with revenues of $0.73 million for the last quarter.
• Analysts have lowered their target prices for Celldex Therapeutics, with a current average price target of $46.67 and several firms maintaining a "Buy" or "Overweight" rating.

Nuveen LLC purchased a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 429,126 shares of the biopharmaceutical company's stock, valued at approximately $7,789,000. Nuveen LLC owned approximately 0.65% of Celldex Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of Celldex Therapeutics by 6,665.9% during the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock valued at $54,000 after acquiring an additional 2,933 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in shares of Celldex Therapeutics during the 4th quarter valued at $121,000. Hsbc Holdings PLC purchased a new position in shares of Celldex Therapeutics during the 4th quarter valued at $233,000. Ameriprise Financial Inc. purchased a new position in shares of Celldex Therapeutics during the 4th quarter valued at $251,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Celldex Therapeutics during the 4th quarter valued at $354,000.

Celldex Therapeutics Stock Down 1.3%

CLDX stock traded down $0.30 during mid-day trading on Friday, reaching $22.08. 1,329,314 shares of the stock traded hands, compared to its average volume of 1,474,976. Celldex Therapeutics, Inc. has a 52 week low of $14.40 and a 52 week high of $47.00. The business has a 50-day moving average of $22.29 and a two-hundred day moving average of $20.64. The firm has a market capitalization of $1.47 billion, a PE ratio of -7.34 and a beta of 1.22.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The company had revenue of $0.73 million during the quarter, compared to analysts' expectations of $1.13 million. On average, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CLDX. Wells Fargo & Company decreased their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating for the company in a report on Wednesday, August 20th. Morgan Stanley decreased their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, May 9th. The Goldman Sachs Group decreased their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday, May 9th. UBS Group decreased their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright decreased their price objective on shares of Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating for the company in a report on Wednesday, August 20th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $46.67.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.